mab_id,target,epitope_residues,epitope_sequence,predicted_kd_nm,binding_mechanism,design_approach,cross_reactivity_fl_her2,internalization_prediction,adc_suitability_score,advantages,challenges,development_status
p95-mAb-001,Juxtamembrane stub,615-635,MPIWKFPDEEGACQPCPINC,15.0,Linear epitope in JM region,Peptide immunization with JM sequence,Yes (JM conserved),Moderate (35% at 4h),6.5,Targets both p95 and FL-HER2,Limited epitope accessibility near membrane,Predicted/Conceptual
p95-mAb-002,Neo-epitope at Met611,611-625,MPIWKFPDEEGACQP,8.0,Neo-epitope specific to p95-CTF611,Immunization with N-terminal p95 peptide,No (neo-epitope specific),Unknown (novel target),5.0,"Specific to p95, no FL-HER2 binding",Limited to p95-CTF611 variant only,Predicted/Conceptual
p95-mAb-003,Membrane-proximal region,640-652,CTHSCVDLDDKGC,25.0,Cysteine-rich membrane-proximal,Structure-based design,Yes (region conserved),Low (20% at 4h),4.5,Accessible on both p95 and FL,"Very close to membrane, steric hindrance",Predicted/Conceptual
p95-Bispecific-001,p95 JM + FL-HER2 Domain IV,615-635 + 557-603,Biparatopic,2.0,Dual targeting p95 and FL-HER2,Bispecific antibody engineering,By design (dual target),High (60% at 4h),8.5,Targets both p95+ and FL-HER2+ cells,"Complex manufacturing, dual optimization",Predicted/Conceptual
MCLA-128 (Zenocutuzumab),HER2 Domain II + HER3,HER2: 266-333,N/A (existing mAb),1.5,Bispecific HER2/HER3,Clinical-stage bispecific,Yes (HER2 Domain II),Moderate,7.0,"Blocks HER2/HER3 signaling, clinical data",Does not directly target p95,Phase 2 Clinical
